Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

Cite this paper

@article{OConnor2006ClinicalEW, title={Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.}, author={Owen O'Connor and Mark Heaney and Lawrence H. Schwartz and Stacie Richardson and Robert D Willim and Barbara Macgregor-Cortelli and Tracey Curly and Craig H. Moskowitz and Carol S. Portlock and Steven M Horwitz and Andrew D. Zelenetz and Stanley R. Frankel and Victoria M. Richon and Paul Marks and William Kevin Kelly}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2006}, volume={24 1}, pages={166-73} }